Zelluna ASA [ZLNA]: Registration of reverse share split

31 Mar 2025 17:16 CEST

Oslo, Norway, 31 March, 2025

Reference is made to the stock exchange notice published by the Zelluna ASA (the
"Company") on 27 March 2025 with key information concerning a reverse share
split in the ratio of 10:1.

The reverse share split has today been registered with the Norwegian Register of
Business Enterprises. After the registration of the reverse share split, the new
number of outstanding shares in the Company is 20,227,066, each with a par value
of NOK 1.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

More information:
Access the news on Oslo Bors NewsWeb site